Evonik LOLA Equivalent: Crystalline Habit & Filtration Rates
Ningbo Inno Pharmchem Co., Ltd. engineers a high-performance drop-in replacement for Evonik's L-Ornithine-L-Aspartate, designed to meet the rigorous demands of parenteral and nutraceutical manufacturing. Our L-Ornithine L-Aspartate salt (CAS: 3230-94-2) delivers identical technical parameters, ensuring seamless integration into existing ammonia metabolism support formulations without re-validation delays. The product is synthesized using high-purity precursors, including (2S)-2,5-diaminopentanoic acid and (2S)-2-aminobutanedioic acid, to guarantee consistent chiral purity and low impurity profiles. For detailed specifications, review our L-Ornithine L-Aspartate salt technical data. This material is suitable for liver health formulation applications and dietary supplement ingredient development, offering a cost-efficient alternative with supply chain reliability.
Crystalline Morphology Technical Specs & 0.22-Micron Sterile Filtration Throughput Impact
The crystalline morphology of LOLA directly influences 0.22-micron sterile filtration throughput in IV bag filling lines. Variations in crystal habit, such as elongated needle structures versus equant block forms, alter filter cake permeability and resistance. Needle-like crystals tend to interlock, creating a dense cake layer that rapidly increases differential pressure, potentially triggering filter change alarms prematurely. Our manufacturing process controls crystallization kinetics to produce a uniform particle-size distribution dominated by equant habits, which form a more porous cake structure. This optimization reduces filter cake resistance and extends filter life. Field experience indicates that humidity fluctuations during storage can cause crystal agglomeration, effectively increasing the apparent particle size and altering filtration dynamics. We recommend storing material in controlled humidity environments to maintain the specified habit profile. Please refer to the batch-specific COA for exact particle size distribution metrics and D90/D10 ratios.
| Parameter | Technical Requirement | Verification Method |
|---|---|---|
| Crystalline Habit | Uniform, non-needle morphology | Optical Microscopy |
| Particle Size Distribution | Consistent D90 range | Laser Diffraction |
| Sterile Filtration Impact | Low pressure drop at 0.22 µm | Throughput Testing |
Trace Heavy Metal PPM Variance & COA Parameters for Purity Grade Verification Across Batches
Trace heavy metal content must remain within strict limits for infusion grade material. Variance in PPM levels across batches can indicate inconsistencies in raw material sourcing or purification efficiency. Ningbo Inno Pharmchem employs rigorous ion exchange and multi-step crystallization processes to control heavy metal residues. The selection of crystallization solvents and the number of recrystallization cycles are optimized to maximize the rejection of metal impurities. Our COA provides batch-specific quantification for lead, arsenic, mercury, and cadmium using ICP-MS methods. Procurement teams should verify that the PPM variance between consecutive batches remains within the acceptable deviation range defined in the purchase specification. Consistent low levels of trace impurities prevent catalytic degradation of the API during storage and ensure compliance with pharmacopeial requirements for parenteral substances.
Specific Rotation Stability Metrics During Prolonged IV Bag Storage
Specific rotation serves as a critical indicator of chiral purity and stability for L-Ornithine L-Aspartate. During prolonged storage in IV bags, exposure to elevated temperatures can accelerate racemization, leading to shifts in specific rotation values. Racemization reduces the enantiomeric excess, which may impact the pharmacological efficacy of the ammonia metabolism support mechanism. Our stability studies monitor rotation metrics under accelerated conditions to ensure the chiral integrity remains stable throughout the shelf life. A deviation in specific rotation may also signal thermal degradation or the formation of diastereomeric impurities. We recommend monitoring rotation values at defined intervals during shelf-life validation and correlating these metrics with color development, as degradation products can sometimes cause yellowing. Please refer to the batch-specific COA for the accepted specific rotation range and related impurity limits.
Buffer pH Adjustment Protocols to Prevent Precipitation When Switching API Sources
When transitioning to a new API source, buffer pH adjustment protocols must be validated to prevent precipitation in the final formulation. Differences in residual solvent levels, trace counter-ions, or crystal habit can shift the solubility curve of the L-Ornithine L-Aspartate salt. Our product is engineered to match the solubility profile of established market references, minimizing the risk of precipitation during pH adjustment. However, formulators should conduct forced degradation studies to confirm that the buffer capacity maintains the API in solution across the intended pH range, particularly in the presence of electrolytes such as sodium chloride. Precipitation events can compromise dosage accuracy and patient safety in parenteral applications. Additionally, variations in dissolution rate due to crystal habit differences may affect the initial pH stabilization time during mixing.
Bulk Packaging Configurations & Technical Specifications for GMP LOLA Procurement
Ningbo Inno Pharmchem supplies GMP compliant supply configurations tailored for large-scale manufacturing. Standard packaging includes double-layered polyethylene bags within 25kg fiber drums or IBC totes, ensuring protection against moisture ingress and mechanical damage. The inner bags are manufactured from food-grade polyethylene with high barrier properties to prevent static discharge and contamination. For bulk shipments, nitrogen flushing is available upon request to further reduce oxidation risk during transit. Logistics planning should account for the hygroscopic nature of amino acid salts; storage facilities must maintain controlled humidity to preserve powder flowability and prevent caking. Our supply chain supports reliable delivery schedules to mitigate production downtime, with packaging options scalable to meet varying production volumes.
Frequently Asked Questions
How does the COA parameter alignment compare to Evonik specifications?
Our COA parameters are aligned to match the technical requirements of Evonik LOLA, including purity, loss on drying, and heavy metal limits. Each batch is tested against these specifications to ensure compatibility with existing quality control protocols.
What are the endotoxin limits for injectable applications?
For parenteral manufacturing, our L-Ornithine L-Aspartate meets strict endotoxin limits suitable for infusion grade material. The specific endotoxin value is reported on the batch-specific COA and is verified using the LAL assay method.
How is batch-to-batch consistency maintained for parenteral manufacturing?
Batch-to-batch consistency is ensured through controlled crystallization processes and rigorous in-process testing. Key metrics such as particle size distribution, specific rotation, and impurity profiles are monitored to minimize variance between production lots.
Sourcing and Technical Support
Ningbo Inno Pharmchem Co., Ltd. provides a reliable source for high-quality L-Ornithine L-Aspartate, supporting both pharmaceutical and nutraceutical applications. Our technical team is available to assist with formulation queries and supply chain coordination. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.